TY - JOUR
T1 - ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections
AU - Arendrup, M. C.
AU - Boekhout, T.
AU - Akova, M.
AU - Meis, J. F.
AU - Cornely, O. A.
AU - Lortholary, O.
AU - Arikan-Akdagli, Sevtap
AU - Cuenca-Estrella, Manuel
AU - Dannaoui, Eric
AU - van Diepeningen, Anne D.
AU - Groll, Andreas H.
AU - Guarro, Josep
AU - Guinea, Jesús
AU - Hope, William
AU - Lackner, Michaela
AU - Lass-Flörl, Cornelia
AU - Lagrou, Katrien
AU - Lanternier, Fanny
AU - Meletiadis, Joseph
AU - Munoz, Patricia
AU - Pagano, Livio
AU - Richardson, Malcolm D.
AU - Roilides, Emmanuel
AU - Tortorano, Anna Maria
AU - Ullmann, Andrew J.
PY - 2014
Y1 - 2014
N2 - The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no exception. This is in part due to the severe underlying conditions typically predisposing patients to these healthcare-related infections (most often severe neutropenia in patients with haematological malignancies), and in part due to the often challenging intrinsic susceptibility pattern of the pathogens that potentially leads to delayed appropriate antifungal treatment. A panel of experts of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and the European Confederation of Medical Mycology (ECMM) undertook a data review and compiled guidelines for the diagnostic tests and procedures for detection and management of rare invasive yeast infections. The rare yeast pathogens were defined and limited to the following genera/species: Cryptococcus adeliensis, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus flavescens, Cryptococcus laurentii and Cryptococcus uniguttulatus (often published under the name Filobasidium uniguttulatum), Malassezia furfur, Malassezia globosa, Malassezia pachydermatis and Malassezia restricta, Pseudozyma spp., Rhodotorula glutinis, Rhodotorula minuta and Rhodotorula mucilaginosa, Sporobolomyces spp., Trichosporon asahii, Trichosporon asteroides, Trichosporon dermatis, Trichosporon inkin, Trichosporon jirovecii, Trichosporon loubieri, Trichosporon mucoides and Trichosporon mycotoxinivorans and ascomycetous ones: Geotrichum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae (incl. S. boulardii) and Saprochaete capitatae (Magnusiomyces (Blastoschizomyces) capitatus formerly named Trichosporon capitatum or Geotrichum (Dipodascus) capitatum) and Saprochaete clavata. Recommendations about the microbiological investigation and detection of invasive infection were made and current knowledge on the most appropriate antifungal and supportive treatment was reviewed. In addition, remarks about antifungal susceptibility testing were made. © 2013 European Society of Clinical Microbiology and Infectious Diseases.
AB - The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no exception. This is in part due to the severe underlying conditions typically predisposing patients to these healthcare-related infections (most often severe neutropenia in patients with haematological malignancies), and in part due to the often challenging intrinsic susceptibility pattern of the pathogens that potentially leads to delayed appropriate antifungal treatment. A panel of experts of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and the European Confederation of Medical Mycology (ECMM) undertook a data review and compiled guidelines for the diagnostic tests and procedures for detection and management of rare invasive yeast infections. The rare yeast pathogens were defined and limited to the following genera/species: Cryptococcus adeliensis, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus flavescens, Cryptococcus laurentii and Cryptococcus uniguttulatus (often published under the name Filobasidium uniguttulatum), Malassezia furfur, Malassezia globosa, Malassezia pachydermatis and Malassezia restricta, Pseudozyma spp., Rhodotorula glutinis, Rhodotorula minuta and Rhodotorula mucilaginosa, Sporobolomyces spp., Trichosporon asahii, Trichosporon asteroides, Trichosporon dermatis, Trichosporon inkin, Trichosporon jirovecii, Trichosporon loubieri, Trichosporon mucoides and Trichosporon mycotoxinivorans and ascomycetous ones: Geotrichum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae (incl. S. boulardii) and Saprochaete capitatae (Magnusiomyces (Blastoschizomyces) capitatus formerly named Trichosporon capitatum or Geotrichum (Dipodascus) capitatum) and Saprochaete clavata. Recommendations about the microbiological investigation and detection of invasive infection were made and current knowledge on the most appropriate antifungal and supportive treatment was reviewed. In addition, remarks about antifungal susceptibility testing were made. © 2013 European Society of Clinical Microbiology and Infectious Diseases.
KW - Clinical guideline
KW - Cryptococcus
KW - Geotrichum
KW - Kodamaea
KW - Malassezia
KW - Pseudozyma
KW - Rhodotorula
KW - Saccharomyces
KW - Saprochaete
KW - Sporobolomyces
KW - Trichosporon
U2 - 10.1111/1469-0691.12360
DO - 10.1111/1469-0691.12360
M3 - Article
SN - 1469-0691
VL - 20
SP - 76
EP - 98
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 3
ER -